NASDAQ: OTLK
Outlook Therapeutics Inc Stock Ownership - Who owns Outlook Therapeutics?

Insider buying vs selling

Have Outlook Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Ghiath M. SukhtianDirector2025-05-274,285,714$1.40
$6.00MBuy
Ghiath M. SukhtianDirector2025-01-173,458,571$2.51
$8.68MBuy

1 of 1

OTLK insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when OTLK insiders and whales buy or sell their stock.

OTLK Shareholders

What type of owners hold Outlook Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ghiath M. Sukhtian188.20%83,599,563$112.02MInsider
Faisal Ghiath Sukhtian125.81%55,884,786$74.89MInsider
Biolexis Pte Ltd57.28%25,443,159$34.09MInsider
Arun Kumar Pillai51.74%22,982,529$30.80MInsider
Pankaj Mohan18.65%8,285,115$11.10MInsider
Syntone Ventures LLC3.84%1,705,438$2.29MInsider
Schonfeld Strategic Advisors LLC3.07%1,364,809$1.83MInstitution
Vanguard Group Inc2.82%1,251,598$1.68MInstitution
Jeff Evanson1.82%808,459$1.08MInsider
Terry Dagnon1.47%653,058$875.10kInsider

1 of 3

OTLK vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
OTLK2.87%97.13%Net Buying
NRXP5.67%94.33%Net Buying
JUNS0.19%32.41%Net Buying
CVM2.30%97.70%Net BuyingNet Buying
MNOV10.54%89.10%

Outlook Therapeutics Stock Ownership FAQ

Who owns Outlook Therapeutics?

Outlook Therapeutics (NASDAQ: OTLK) is owned by 13.37% institutional shareholders, 452.10% Outlook Therapeutics insiders, and 0.00% retail investors. Ghiath M. Sukhtian is the largest individual Outlook Therapeutics shareholder, owning 83.60M shares representing 188.20% of the company. Ghiath M. Sukhtian's Outlook Therapeutics shares are currently valued at $111.19M.

If you're new to stock investing, here's how to buy Outlook Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.